Huons Co., Ltd. (KOSDAQ:243070)

Market Cap	307.61B +6.5%
Revenue (ttm)	620.77B +5.2%
Net Income	42.66B +44.8%
EPS	3,600.00 +51.6%
Shares Out	11.65M
PE Ratio	7.33
Forward PE	n/a
Dividend	920.00 (3.45%)
Ex-Dividend Date	Apr 2, 2026

Volume	21,520
Average Volume	21,195
Open	26,700
Previous Close	26,700
Day's Range	26,200 - 26,750
52-Week Range	24,550 - 32,200
Beta	0.15
RSI	49.26
Earnings Date	May 15, 2026

About Huons

Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, anti-coagulant, antiviral, central nervous system, antibiotic, well-being, urogenital system, and other chemotherapeutic products; and injection products, such as anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1965
• Employees: 912
• Stock Exchange: KOSDAQ
• Ticker Symbol: 243070

Financial Performance

In 2025, Huons's revenue was 620.77 billion, an increase of 5.17% compared to the previous year's 590.23 billion. Earnings were 42.66 billion, an increase of 44.84%.